Preview – CDR404


Urgent need for new therapies in solid tumors
MAGE-A4 is commonly overexpressed in difficult-to-treat solid tumors including non-small cell lung, head and neck, synovial sarcoma, bladder, and gynecological malignancies. Redirecting T cell migration towards MAGE-A4 positive tumors is likely to be an important treatment option for these patients.

What is MAGE-A4?
Melanoma-associated antigen A4 (MAGE-A4) is a protein that has minimal or no presence in healthy tissue but exhibits increased expression in several solid tumors. Tumor cells display MAGE-A4 fragments on their cell membrane via the Human Leukocyte Antigen (HLA) protein. The immune system, namely T cells, have the potential to identify these MAGE-A4 peptides in a highly specific manner, promoting tumor cell killing. 

CDR404 – a novel molecule for cancer treatment
Currently, cancer-specific proteins such as MAGE-A4 can only be targeted by highly complex treatments, like engineered cell therapies, which are individualized, expensive, and require several weeks to be produced. CDR404 is a potent off-the-shelf treatment and is a first-of-its-kind, antibody-based MAGE-A4 T cell engager for MAGE-A4 positive solid tumors. 

Phase 1 clinical trial of CDR404 in solid tumors – recruiting
The CDR404-001 trial is evaluating the safety, tolerability, pharmacokinetics, and initial signs of clinical efficacy of CDR404. This first-in-human study is an open-label, multi-center trial, investigating escalating doses of CDR404 in patients who are positive for HLA-A*02:01 with solid tumors expressing MAGE-A4. Further information can be found at NCT06402201 or contact